RDUS - ラディウス・ヘルス （Radius Health Inc.） ラディウス・ヘルスRDUSのチャート
RDUSの企業情報
| symbol | RDUS |
|---|---|
| 会社名 | Radius Health Inc （ラディウス・ヘルス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ラジウス・ヘルス（Radius Health Inc）は生物医薬品企業である。同社は骨粗鬆症、腫瘍学および内分泌疾患の分野における治療法の開発に焦点を当てる。同社の治験薬候補であるTYMLOS（アバロパラチド-SC）注射は骨折リスクの高い骨粗鬆症を有する閉経後女性の治療のために開発される。同社の臨床パイプラインには骨粗鬆症に使用する可能性のある治験用アバロパラチド経皮パッチと、ホルモン駆動またはホルモン耐性乳がん、閉経後女性の血管運動症状の潜在的使用に関する治験薬elacestrant（RAD1901）を含まれる。RAD140は非ステロイド系の選択的アンドロゲン受容体モジュレーター（SARM）である。RAD140はホルモン受容体陽性乳癌の潜在的使用のために開発される。 ラディウス・ヘルスは、米国の婦人科領域に特化したバイオ医薬品会社。骨粗鬆症患者向け治療薬を開発するだけでなく、他の内分泌媒介性疾患に焦点を当て事業を展開。主要製品候補は、骨粗鬆症の治療のための骨同化皮下注射Abaloparatide-SC。臨床製品ポ―トフォリオとしては、経口薬で選択的エストロゲン受容体低下剤RAD1901がある。 Radius Health Inc. is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome. |
| 本社所在地 | 950 Winter Street Waltham MA 02451 USA |
| 代表者氏名 | Kurt C. Graves Kurt C. Graves |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-551-4000 |
| 設立年月日 | 39479 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 561人 |
| url | www.radiuspharm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rdus |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -242.34700 |
| 終値（lastsale） | 18.83 |
| 時価総額（marketcap） | 856321647.65 |
| 時価総額 | 時価総額（百万ドル） 862.23360 |
| 売上高 | 売上高（百万ドル） 58.30800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 803.73660 |
| 当期純利益 | 当期純利益（百万ドル） -259.29700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Radius Health Inc revenues increased from $980K to $37.2M. Net loss increased 4% to $130.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 26% to $49.2M (expense) General and administrative increase of 10% to $96.6M (expense). |
RDUSのテクニカル分析
RDUSのニュース
Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential 2022/07/16 13:30:00 Stocks Register
Radius Health Inc. (NASDAQ:RDUS) shares, rose in value on Friday, 07/15/22, with the stock price up by 0.20% to the previous day’s close as strong demand from buyers drove the stock to $10.13. Actively observing the price movement in the last trading, the stock closed the session at $10.11, falling within a range of $10.08 … Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential Read More »
Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 2022/07/13 13:30:00 Marketing Sentinel
In the last trading session, 1.11 million shares of the Radius Health Inc. (NASDAQ:RDUS) were traded, and its beta was 0.55. Most recently the company’s share price was $10.14, and it changed around -$0.06 or -0.59% from the last close, which brings the market valuation of the company to $475.67M. RDUS currently trades at a … Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 Read More »
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium 2022/07/07 22:30:00 GlobeNewswire
BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ .
Radius Health Publishes Investor Presentation Outlining Company''s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium 2022/07/07 22:30:00 Benzinga
Urges stockholders to vote " FOR " Radius'' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS ) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ . The document discusses the Company''s progress since 2020 and also outlines the comprehensive strategic review process conducted by the Radius Board of Directors, which resulted in its unanimous approval of the Company''s acquisition by Gurnet Point Capital and Patient Square Capital at a significant premium. Stockholders are urged to vote "FOR" all three of the Company''s highly qualified, independent nominees on the BLUE proxy card at its upcoming Annual Meeting of Stockholders, which will be held online on July 26, 2022. YOUR VOTE IS IMPORTANT VOTE "FOR" RADIUS'' THREE NOMINEES ON THE BLUE PROXY CARD TODAY 509 Madison Avenue New York, NY 10022 Email: RDUS@info.morrowsodali.com Call toll-free at (800) 662-5200 (in North America) or +1 (203) 658-9400 (outside of North America) About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology.
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm 2022/07/06 15:15:00 Wallstreet:Online
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to
Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential 2022/07/16 13:30:00 Stocks Register
Radius Health Inc. (NASDAQ:RDUS) shares, rose in value on Friday, 07/15/22, with the stock price up by 0.20% to the previous day’s close as strong demand from buyers drove the stock to $10.13. Actively observing the price movement in the last trading, the stock closed the session at $10.11, falling within a range of $10.08 … Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential Read More »
Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 2022/07/13 13:30:00 Marketing Sentinel
In the last trading session, 1.11 million shares of the Radius Health Inc. (NASDAQ:RDUS) were traded, and its beta was 0.55. Most recently the company’s share price was $10.14, and it changed around -$0.06 or -0.59% from the last close, which brings the market valuation of the company to $475.67M. RDUS currently trades at a … Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 Read More »
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium 2022/07/07 22:30:00 GlobeNewswire
BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ .
Radius Health Publishes Investor Presentation Outlining Company''s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium 2022/07/07 22:30:00 Benzinga
Urges stockholders to vote " FOR " Radius'' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS ) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ . The document discusses the Company''s progress since 2020 and also outlines the comprehensive strategic review process conducted by the Radius Board of Directors, which resulted in its unanimous approval of the Company''s acquisition by Gurnet Point Capital and Patient Square Capital at a significant premium. Stockholders are urged to vote "FOR" all three of the Company''s highly qualified, independent nominees on the BLUE proxy card at its upcoming Annual Meeting of Stockholders, which will be held online on July 26, 2022. YOUR VOTE IS IMPORTANT VOTE "FOR" RADIUS'' THREE NOMINEES ON THE BLUE PROXY CARD TODAY 509 Madison Avenue New York, NY 10022 Email: RDUS@info.morrowsodali.com Call toll-free at (800) 662-5200 (in North America) or +1 (203) 658-9400 (outside of North America) About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology.
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm 2022/07/06 15:15:00 Wallstreet:Online
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to
Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential 2022/07/16 13:30:00 Stocks Register
Radius Health Inc. (NASDAQ:RDUS) shares, rose in value on Friday, 07/15/22, with the stock price up by 0.20% to the previous day’s close as strong demand from buyers drove the stock to $10.13. Actively observing the price movement in the last trading, the stock closed the session at $10.11, falling within a range of $10.08 … Understanding Radius Health Inc. (NASDAQ: RDUS)’s Growth Potential Read More »
Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 2022/07/13 13:30:00 Marketing Sentinel
In the last trading session, 1.11 million shares of the Radius Health Inc. (NASDAQ:RDUS) were traded, and its beta was 0.55. Most recently the company’s share price was $10.14, and it changed around -$0.06 or -0.59% from the last close, which brings the market valuation of the company to $475.67M. RDUS currently trades at a … Why Radius Health Inc. (NASDAQ: RDUS) Stock Should Not Be Discarded By Investors In 2022 Read More »
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium 2022/07/07 22:30:00 GlobeNewswire
BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ .
Radius Health Publishes Investor Presentation Outlining Company''s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium 2022/07/07 22:30:00 Benzinga
Urges stockholders to vote " FOR " Radius'' highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS ) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/ . The document discusses the Company''s progress since 2020 and also outlines the comprehensive strategic review process conducted by the Radius Board of Directors, which resulted in its unanimous approval of the Company''s acquisition by Gurnet Point Capital and Patient Square Capital at a significant premium. Stockholders are urged to vote "FOR" all three of the Company''s highly qualified, independent nominees on the BLUE proxy card at its upcoming Annual Meeting of Stockholders, which will be held online on July 26, 2022. YOUR VOTE IS IMPORTANT VOTE "FOR" RADIUS'' THREE NOMINEES ON THE BLUE PROXY CARD TODAY 509 Madison Avenue New York, NY 10022 Email: RDUS@info.morrowsodali.com Call toll-free at (800) 662-5200 (in North America) or +1 (203) 658-9400 (outside of North America) About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology.
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm 2022/07/06 15:15:00 Wallstreet:Online
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to